These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 38250045)

  • 41. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
    Medikonda R; Pant A; Lim M
    Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [
    McNeal KC; Reeves KM; Song PN; Lapi SE; Sorace AG; Larimer BM
    Nucl Med Biol; 2024; 134-135():108918. PubMed ID: 38772123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8
    Liu F; Zhou Q; Jiang HF; Zhang TT; Miao C; Xu XH; Wu JX; Yin SL; Xu SJ; Peng JY; Gao PP; Cao X; Pan F; He X; Chen XQ
    J Exp Clin Cancer Res; 2023 May; 42(1):118. PubMed ID: 37161450
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
    Surendran A; Jenner AL; Karimi E; Fiset B; Quail DF; Walsh LA; Craig M
    J Pharmacol Exp Ther; 2023 Oct; 387(1):66-77. PubMed ID: 37442619
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interferon gamma immunoPET imaging to evaluate response to immune checkpoint inhibitors.
    Hackett JB; Ramos N; Barr S; Bross M; Viola NT; Gibson HM
    Front Oncol; 2023; 13():1285117. PubMed ID: 38130991
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
    Saha D; Martuza RL; Rabkin SD
    Cancer Cell; 2017 Aug; 32(2):253-267.e5. PubMed ID: 28810147
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy.
    Passaro C; Alayo Q; De Laura I; McNulty J; Grauwet K; Ito H; Bhaskaran V; Mineo M; Lawler SE; Shah K; Speranza MC; Goins W; McLaughlin E; Fernandez S; Reardon DA; Freeman GJ; Chiocca EA; Nakashima H
    Clin Cancer Res; 2019 Jan; 25(1):290-299. PubMed ID: 30279232
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy.
    Otani Y; Yoo JY; Lewis CT; Chao S; Swanner J; Shimizu T; Kang JM; Murphy SA; Rivera-Caraballo K; Hong B; Glorioso JC; Nakashima H; Lawler SE; Banasavadi-Siddegowda Y; Heiss JD; Yan Y; Pei G; Caligiuri MA; Zhao Z; Chiocca EA; Yu J; Kaur B
    Clin Cancer Res; 2022 Apr; 28(7):1460-1473. PubMed ID: 35022322
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma.
    Chen L; Zhou C; Chen Q; Shang J; Liu Z; Guo Y; Li C; Wang H; Ye Q; Li X; Zu S; Li F; Xia Q; Zhou T; Li A; Wang C; Chen Y; Wu A; Qin C; Man J
    Mol Ther Oncolytics; 2022 Mar; 24():522-534. PubMed ID: 35229030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma.
    Maggio D; Ho WS; Breese R; Walbridge S; Wang H; Cui J; Heiss JD; Gilbert MR; Kovach JS; Lu RO; Zhuang Z
    J Neurooncol; 2020 Jun; 148(2):231-244. PubMed ID: 32342332
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CXCL10 and Nrf2-upregulated mesenchymal stem cells reinvigorate T lymphocytes for combating glioblastoma.
    Mao J; Li J; Chen J; Wen Q; Cao M; Zhang F; Li B; Zhang Q; Wang Z; Zhang J; Shen J
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056897
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
    Natarajan A; Mayer AT; Reeves RE; Nagamine CM; Gambhir SS
    Mol Imaging Biol; 2017 Dec; 19(6):903-914. PubMed ID: 28247187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of an ImmunoPET Tracer for IL-12 in a Preclinical Model of Inflammatory Immune Responses.
    Viola NT; Glassbrook JE; Kalluri JR; Hackett JB; Wicker MN; Sternberg J; Gibson HM
    Front Immunol; 2022; 13():870110. PubMed ID: 35634303
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced therapeutic efficacy for glioblastoma immunotherapy with an oncolytic herpes simplex virus armed with anti-PD-1 antibody and IL-12.
    Wang L; Zhou X; Chen X; Liu Y; Huang Y; Cheng Y; Ren P; Zhao J; Zhou GG
    Mol Ther Oncol; 2024 Jun; 32(2):200799. PubMed ID: 38681801
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune involvement of the contralateral hemisphere in a glioblastoma mouse model.
    Crommentuijn MHW; Schetters STT; Dusoswa SA; Kruijssen LJW; Garcia-Vallejo JJ; van Kooyk Y
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303613
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
    Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    Shevtsov M; Pitkin E; Ischenko A; Stangl S; Khachatryan W; Galibin O; Edmond S; Lobinger D; Multhoff G
    Front Immunol; 2019; 10():454. PubMed ID: 30967859
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of
    Kol A; Fan X; Wazynska MA; van Duijnhoven SMJ; Giesen D; Plat A; Van Eenennaam H; Elsinga PH; Nijman HW; de Bruyn M
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.